What question did this study set out to answer?

This study examines how recipient age and cytomegalovirus serostatus influence graft and overall survival in liver transplant recipients.

January 14, 2026Open Access

P-1797. The Effect of Recipient Age and Cytomegalovirus Sero-status on Patient and Graft Survival in Liver Transplant Recipients

Puntos clave

This study examines how recipient age and cytomegalovirus serostatus influence graft and overall survival in liver transplant recipients.
Retrospective analysis of transplant data from 89,753 liver transplant recipients
Recipient age categorization into three groups: ≥60, 40-60, and <40 years
Stratification of outcomes based on CMV serostatus using survival curves and hazard ratios
Analysis included one- and five-year post-transplant survival rates.
Recipients aged 40-60 had worse graft survival associated with CMV seropositivity
CMV D-R- status was linked to better overall survival compared to other serostatus groups
All-cause mortality was significantly affected by recipient age and CMV serostatus over the five-year period
Increased awareness and targeted strategies are recommended for managing transplant recipients' risks.

Resumen

Abstract Background Cytomegalovirus (CMV) may impact allograft function and overall survival in solid organ transplant recipients in various direct or indirect mechanisms. The association between recipient age and donor-recipient CMV status and outcomes of liver transplantation (LT) are unclear. Methods Retrospective analysis of the Scientific Registry of Transplant Recipients for LT recipients ≥18 years old between 2000-2020 (N=89,753) was conducted. Recipient age-based stratification analysis was performed to compare the association of CMV serostatus and recipient age on overall and graft survival after LT. Survival curves were generated using the Kaplan-Meier method. All-cause mortality and graft failure hazard ratios were calculated at one- and five-years post-LT. Results LT recipients were stratified in to age groups (years) of ≥ 60 (36,636; 40.8%), 40-60 (43,921; 48.9%), and 40 (9,196; 10.3%). Among these LT recipients, various CMV serostatus groups were D-R- (12,521;13.8%), D+R- (20,815; 23.0%), D-R+ (19.830; 21.9%), and D+R+ (37,395; 41.3%). In the age-based stratification analysis, all CMV seropositive statuses (D+R-, D-R+, D+R+) when compared to CMV D-/R-, were negatively associated with overall and graft survival at both one- and five-years post-LT (p 0.0001), group. The negative association of CMV seropositivity on one-year and five-year overall and graft survival was most pronounced in 40-60 years group (Fig 1, 2) when compared to the other two age groups. Conclusion During the current era of effective CMV prophylaxis, LT recipients in the 40-60-year age group are at the highest risk of CMV seropositivity (D+R-, D-R+, D+R+) associated worse overall and graft survival at both one- and five-years post-LT. Identification of age-based risk factors, increased awareness, as well as effective diagnostic and therapeutic strategies are needed to mitigate this risk. Disclosures Abhay Dhand, MD, Eurofins Viracor: Advisor/Consultant|Eurofins Viracor: Honoraria|Merck: Advisor/Consultant|Merck: Honoraria

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo